Feedback-informed treatment: A systematic review and meta-analysis of the partners for change outcome management system.

2020 ◽  
Vol 67 (6) ◽  
pp. 723-735
Author(s):  
Jan Hyld Pejtersen ◽  
Bjørn Christian Arleth Viinholt ◽  
Helle Hansen
Keyword(s):  
Systematic Review ◽  
Management System ◽  
Meta Analysis ◽  
Outcome Management ◽  
Informed Treatment ◽  
Feedback Informed Treatment

scholarly journals Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis

2013 ◽  
Vol 44 (3) ◽  
pp. 449-468 ◽  
Author(s):  
P. Hutton ◽  
P. J. Taylor
Keyword(s):  
Systematic Review ◽  
Cognitive Behavioural Therapy ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Behavioural Therapy ◽  
Control Treatment ◽  
Clinical Equipoise ◽  
Random Allocation ◽  
Cognitive Behavioural ◽  
Informed Treatment

BackgroundClinical equipoise regarding preventative treatments for psychosis has encouraged the development and evaluation of psychosocial treatments, such as cognitive behavioural therapy (CBT).MethodA systematic review and meta-analysis was conducted, examining the evidence for the effectiveness of CBT-informed treatment for preventing psychosis in people who are not taking antipsychotic medication, when compared to usual or non-specific control treatment. Included studies had to meet basic quality criteria, such as concealed and random allocation to treatment groups.ResultsOur search produced 1940 titles, out of which we found seven completed trials (six published). The relative risk (RR) of developing psychosis was reduced by more than 50% for those receiving CBT at every time point [RR at 6 months 0.47, 95% confidence interval (CI) 0.27–0.82, p = 0.008 (fixed-effects only: six randomized controlled trials (RCTs), n = 800); RR at 12 months 0.45, 95% CI 0.28–0.73, p = 0.001 (six RCTs, n = 800); RR at 18–24 months 0.41, 95% CI 0.23–0.72, p = 0.002 (four RCTs, n = 452)]. Heterogeneity was low in every analysis and the results were largely robust to the risk of an unpublished 12-month study having unfavourable results. CBT was also associated with reduced subthreshold symptoms at 12 months, but not at 6 or 18–24 months. No effects on functioning, symptom-related distress or quality of life were observed. CBT was not associated with increased rates of clinical depression or social anxiety (two studies).ConclusionsCBT-informed treatment is associated with a reduced risk of transition to psychosis at 6, 12 and 18–24 months, and reduced symptoms at 12 months. Methodological limitations and recommendations for trial reporting are discussed.

scholarly journals Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hojin Oh ◽  
Hai Duc Nguyen ◽  
In Mo Yoon ◽  
Byung-Ryong Ahn ◽  
Min-Sun Kim
Keyword(s):  
Systematic Review ◽  
Bayesian Inference ◽  
Quality Management ◽  
Randomized Controlled Trials ◽  
Management System ◽  
Quality Management System ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Dipeptidyl Peptidase 4 Inhibitors

AbstractGemigliptin is one of the latest dipeptidyl peptidase-4 inhibitors developed by LG Life Sciences. Since the early 2000s, several randomized controlled trials (RCTs) of gemigliptin have been conducted. However, no study has directly compared its antidiabetic effects through a systematic review and meta-analysis. Therefore, in this study, we performed a systematic review and meta-analysis on RCTs. In particular, a subsequent meta-analysis was performed using Bayesian inference, and an updated quality management system model was integrated throughout our study. The mean differences and 95% confidence intervals for glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), homeostatic model assessment beta cell function (HOMA-β), and low-density lipoprotein (LDL) were evaluated for the efficacy outcomes of gemigliptin as compared to those of placebo and other oral antidiabetic drugs (OADs). In conclusion, we found that gemigliptin was superior to placebo and comparable to other OADs in terms of the effect on HbA1c, FPG, HOMA-β, and LDL. Further, gemigliptin was more effective than other OADs in HbA1c and HOMA-β in Bayesian inference analysis and statistically significant to other OADs in HbA1c and HOMA-β in sensitivity analysis excluding metformin. However, to confirm the results, more studies need to be analysed and the minimum clinically important difference must be applied.

The effects of low-ratio n-6/n-3 PUFA on biomarkers of inflammation: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen
Keyword(s):  
Systematic Review ◽  
Fatty Acid ◽  
Polyunsaturated Fatty Acid ◽  
Meta Analysis ◽  
Chain Polyunsaturated Fatty Acid ◽  
Inflammation Markers ◽  
Pufa Supplementation ◽  
Long Chain

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.

Sign in / Sign up

Export Citation Format

Share Document